Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jul 31:11:431-437.
doi: 10.2147/IJWH.S178349. eCollection 2019.

Triple-negative breast cancer: current perspective on the evolving therapeutic landscape

Joe Mehanna  1 , Fady Gh Haddad  1 , Roland Eid  1 , Matteo Lambertini  2   3 , Hampig Raphael Kourie  1
Affiliations

Triple-negative breast cancer: current perspective on the evolving therapeutic landscape

Joe Mehanna et al. Int J Womens Health. .

Abstract

Triple-negative breast cancer (TNBC) is known to have a poor prognosis and limited treatment options, namely chemotherapy. Different molecular studies have recently classified TNBC into different subtypes opening the door to potential new-targeted treatment options. In this review, we discuss the current standard of care in the treatment of TNBC in the neoadjuvant, adjuvant and metastatic settings. In addition, we summarize the ongoing phase III clinical trials evaluating different associations between the 3 pillars of anticancer treatment: chemotherapy, targeted therapy and immunotherapy.

Keywords: PARP inhibitors; breast cancer; immunotherapy; triple-negative.

PubMed Disclaimer

Conflict of interest statement

Matteo Lambertini served as a consultant for Teva and received honoraria from Theramex and Takeda outside the submitted work. All remaining authors declared no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Basal-like subtype and triple-negative breast cancer.
See this image and copyright information in PMC

References

    1. Ghoncheh M, Pournamdar Z, Salehiniya H. Incidence and mortality and epidemiology of breast cancer in the world. Asian Pac J Cancer Prev. 2016;17(S3):43–46. doi:10.7314/apjcp.2016.17.4.2119 - DOI - PubMed
    1. Dawson SJ, Provenzano E, Caldas C. Triple negative breast cancers: clinical and prognostic implications. Eur J Cancer. 2009;45(Suppl 1):27–40. doi:10.1016/S0959-8049(09)70013-9 - DOI - PubMed
    1. Lin NU, Vanderplas A, Hughes ME, et al. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer. 2012;118(22):5463–5472. doi:10.1002/cncr.27581 - DOI - PMC - PubMed
    1. Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750–2767. doi:10.1172/JCI45014 - DOI - PMC - PubMed
    1. Lehmann BD, Jovanović B, Chen X, et al. Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection. PLoS One. 2016;11(6):e0157368. doi:10.1371/journal.pone.0157368 - DOI - PMC - PubMed